PT - JOURNAL ARTICLE AU - Vilcapoma, Javier AU - Aliyeva, Asmer AU - Hayden, Andrew AU - Chandrasekaran, Arun Richard AU - Zhou, Lifeng AU - Abraham Punnoose, Jibin AU - Yang, Darren AU - Hansen, Clinton AU - Shiu, Simon Chi-Chin AU - Russell, Alexis AU - George, Kirsten St. AU - Wong, Wesley P. AU - Halvorsen, Ken TI - A non-enzymatic test for SARS-CoV-2 RNA using DNA nanoswitches AID - 10.1101/2023.05.31.23290613 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.31.23290613 4099 - http://medrxiv.org/content/early/2023/06/04/2023.05.31.23290613.short 4100 - http://medrxiv.org/content/early/2023/06/04/2023.05.31.23290613.full AB - The emergence of a highly contagious novel coronavirus in 2019 led to an unprecedented need for large scale diagnostic testing. The associated challenges including reagent shortages, cost, deployment delays, and turnaround time have all highlighted the need for an alternative suite of low-cost tests. Here, we demonstrate a diagnostic test for SARS-CoV-2 RNA that provides direct detection of viral RNA and eliminates the need for costly enzymes. We employ DNA nanoswitches that respond to segments of the viral RNA by a change in shape that is readable by gel electrophoresis. A new multi-targeting approach samples 120 different viral regions to improve the limit of detection and provide robust detection of viral variants. We apply our approach to a cohort of clinical samples, positively identifying a subset of samples with high viral loads. Since our method directly detects multiple regions of viral RNA without amplification, it eliminates the risk of amplicon contamination and renders the method less susceptible to false positives. This new tool can benefit the COVID-19 pandemic and future emerging outbreaks, providing a third option between amplification-based RNA detection and protein antigen detection. Ultimately, we believe this tool can be adapted both for low-resource onsite testing as well as for monitoring viral loads in recovering patients.Competing Interest StatementK.H. and W.P.W were joint inventors of DNA nanoswitches and hold several patents on the core technology. A.R.C., L.Z., D.Y., and C.H. are also inventors on nanoswitch related patents.Funding StatementResearch reported in this publication was supported by the National Science Foundation under award CBET2030279 to K.H. and W.P.W. and by the National Institutes of Health through the National Institute of General Medical Sciences under award R35GM124720 to K.H. and R35GM119537 to W.P.W. Funding for sequencing was provided by the New York Community Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the New York State Department of Health gave ethical approval for this work under approved study number 07-022I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors